BEDFORD, Mass., Dec. 21, 2009 /PRNewswire-FirstCall/ -- Hologic, Inc. (Hologic or the Company) (NASDAQ: HOLX), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced that the jury in the patent infringement lawsuit against SenoRx brought by Hologic, Cytyc Corp., and Hologic L.P., Inc. in the U.S. District Court for the Northern District of California has returned a verdict in favor of SenoRx. The suit alleges SenoRx's Contura infringes claims 4 and 8 of U.S. Patents 6,413,204 and 6,482,142, respectively. The jury found that claim 4 was not infringed and found that both claims were not valid. SenoRx had previously admitted infringement of claim 8. "We are obviously disappointed in the jury's finding, however we believe the decision was based in part on an incorrect claim construction," said Mark Casey, Senior Vice President and General Counsel. "We plan to appeal the matter to the Court of Appeals for the Federal Circuit."
About Hologic, Inc.
Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia, permanent contraception, osteoporosis assessment, preterm birth risk assessment, mini C-arm for extremity imaging and molecular diagnostic products including HPV and reagents for a variety of DNA and RNA analysis applications.
Hologic and Cytyc and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.
Forward-Looking Statement Disclaimer
This News Release may contain forward-looking information that involves risks and uncertainties, including statements about litigation activities. There can be no assurance that Hologic will prevail in the appeal referenced above. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to the data or statements presented herein to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such data or statements are based. Certain factors that could adversely affect the Company's business and prospects are described in Hologic filings with the Securities and Exchange Commission.
Deborah R. Gordon
Vice President, Investor Relations